semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Bipolar Disorder Patients with bipolar disorder in major depressive episode according to DSM-IV MADRS score of at least 20 points at screening and baseline 70 years of age Unchanged dose of mood stabilising medication for at least six weeks prior to Voluntary, informed and written consent  Non-affective psychotic symptoms at screening Pregnancy or breast-feeding Fertile women without appropriate contraception (the pill, IUD, or contraceptive injection) Substance dependence during the last three months prior to baseline Mental retardation and organic brain disorders Suicide risk that mandates specific measures Novel (within three months) or unstable medical conditions Clinically significant abnormal results on medical examination or blood samples Exposure to escitalopram during the last three months Allergic reactions to citalopram or escitalopram
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Insomnia Adults with history of sleeplessness  Allergic to investigational drug Any conditions and medications that may interfere with study drug evaluation
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Brain and Central Nervous System Tumors Cognitive/Functional Effects Neurotoxicity Solid Tumor Histopathologically confirmed extracranial primary malignancy Multiple (i.e., > 3) brain metastases OR < 3 metastases with at least 1 metastasis > 4.0 cm in diameter Not eligible for radiosurgery No requirement for immediate whole-brain radiotherapy No metastases to the midbrain or brainstem  Zubrod performance status 0-2 Life expectancy ≥ 8 weeks Platelet count > 100,000/mm^3 ANC > 1,500/mm^3 Hemoglobin ≥ 10 g/dL BUN < 25 mg/dL Creatinine < 1.5 mg/dL Bilirubin < 1.5 mg/dL ALT ≤ 2 times normal Sodium > 136 mg/dL
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bipolar Disorder Male or female in or out-patients at least 18 years of age Patient must have a diagnosis of bipolar I disorder and currently display acute manic or mixed episodes (with or without psychotic features) according to the DSM-IV based on clinical assessment Patients must have a level of understanding sufficient to agree to all tests and examinations required by the protocol Patients must have a Y-MRS total score of greater than or equal to 20 at both visits 1 & 2 Patients must be considered reliable  Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months Current or past diagnosis of schizophrenia or other psychotic disorder (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV Documented history of intolerance to olanzapine or Lithium Carbonate Treatment with clozapine within 4 weeks prior to visit 2. Treatment with other antipsychotic drugs or mood stabilizers within 2 days prior to visit 2
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Insomnia Chronic insomnia and taking greater than or equal to 10 mg zolpidem at least 4 times per week Has been prescribed zolpidem for difficulty in initiating sleep Must report chronic use of zolpidem greater than or equal to10 mg therapy for a minimum of 3 months prior to entry into Period 1 of the study Must have taken zolpidem greater than or equal to 10 mg therapy for at least 4 of 7 days each week of the 4 weeks immediately prior to entry into the double blind phase, Period 2 Expressed a willingness to discontinue zolpidem therapy Habitual bedtime is between 9:00 PM and 1:00 AM based on sleep history Negative test result for hepatitis B surface antigen and hepatitis C virus antibody Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study  Known hypersensitivity to ramelteon, zolpidem, or melatonin Participated in any other investigational study and/or taken any investigational drug within 30 days prior to the first dose of run-in study medication Sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the first night of run-in study medication History of fibromyalgia, history of seizures, sleep apnea, restless leg syndrome, periodic leg syndrome, chronic obstructive pulmonary disease, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder History of drug addiction or drug abuse within the past 12 months History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition revised and/or regularly consumes more than 2 alcoholic drinks per day Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of run-in study medication Body mass index of less than 18 or greater than 34 (weight /height2) Any clinically important abnormal finding as documented by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator Positive hepatitis panel
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 2.0-18.0,  Insomnia Sleep Disorder Male or female between the ages of 2 years and 18 years Written consent must be obtained form the parent/legal guardian for all minors. Written assent must be obtained from all minors > 6 years of age Female subjects of child-bearing potential must not be pregnant and if females are fertile and sexually active, must have documented a negative urine HCG and assure use of effective contraception acceptable to the investigator (abstinence accepted) during the study period Subjects must meet the following for a diagnosis of insomnia as determined by the subject's private physician or study investigator and subject's history the complaint is significant difficulty (defined by frequency, severity, and/or chronicity) initiating or maintaining sleep;. The problem is viewed problematic by the child and/or caregiver the sleep disturbance causes clinically significant impairment in school performance, behavior, learning, or development for the child as reported by the child and/or caregiver the sleep disturbance does not occur exclusively in the context of an intrinsic dyssomnia such as narcolepsy, restless legs syndrome, or sleep-related breathing disorders; a circadian rhythm disorder; or a parasomnia the sleep disturbance is not attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication  Pregnancy and/or breastfeeding The presence of any untreated (where treatment is available), or unstable, progressive, or evolving clinically significant renal, endocrine, hepatic, respiratory, cardiovascular, neurologic, hematologic, immunologic, cerebrovascular disease or malignancy Elevations in screening blood tests of renal (SCr) and liver (ALT, AST and/or bilirubin) > 2 times the upper limit of normal for age Receiving any medications that may modulate Zolpidem metabolism, primarily drugs that will enhance or reduce the activity of CYP450 3A, 2C9, or 2D6 activity. Note: If patient is receiving a medication that might be considered an inducer or an inhibitor, please discuss with the PI prior to excluding them Receiving any medications with sleep-impairing properties at a dose/dose interval that would be judged by the study investigator as to interfere with the assessment of Zolpidem sleep response Currently using any systemic contraceptive steroids including: oral contraceptives, transdermal patch, vaginal insert, levonorgestrel implant and medroxyprogesterone acetate contraceptive injection
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neuroendocrine Tumors Must have histologically confirmed metastatic low-grade neuroendocrine neoplasms. Small cell lung cancers, paragangliomas and pheochromocytomas are excluded. Pathologic diagnosis must be confirmed at UWCCC. Grading must be confirmed by pathologic review performed at UWCCC Must have measurable disease Must have radiographic evidence of disease progression following any prior systemic therapy, chemoembolization, bland embolization, surgery, or observation Must be ≥ 4 weeks from the completion of major surgery, chemotherapy, or other systemic therapy or local liver therapy to study registration Must be ≥ 3 weeks from the completion of radiation therapy to study registration The following laboratory values are to be obtained within 14 days prior to registration: Absolute neutrophils count (ANC) ≥ 1000/mm3; Platelets ≥ 75,000/mm3; Hemoglobin ≥ 8.0 g/dL; Total bilirubin less than or equal 2.0 X the upper limit of normal (ULN); AST less than or equal to 3 X ULN or less than or equal 5 X ULN if liver metastases are present; Creatinine less than or equal ULN; Serum sodium within normal limits PS = 0-2 Capable of understanding the investigational nature, potential risks and benefits fo the study and able to provide valid informed consent Must have available tissue specimens to be analyzed for pathologic confirmation Age ≥ 18 years
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C, Chronic adult patients, >=18 years of age chronic hepatitis C, genotype 1 insulin resistance  other forms of liver disease cirrhosis previous treatment for chronic hepatitis C insulin treatment during prior 2 weeks type 1 diabetes
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Bipolar Disorder Provision of written informed consent before initiation of any study-related procedures Men and women aged 18 to 65 years A documented clinical diagnosis according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) meeting 296.4x Bipolar I disorder, most recent episode manic, 296.6x Bipolar I disorder, most recent episode mixed, or 296.5x Bipolar I disorder, most recent episode depressed PSQI total score of >=5 MADRS total score of <=12 YMRS total score of <= 12 Female patients of childbearing potential must have a negative urine pregnancy test at enrollment and be willing to use a reliable method of birth control, i.e., double-barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device or tubal ligation, during the study Be able to understand and comply with the requirements of the study, as judged by the investigator Outpatient status at enrollment  Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status Presence of prohibited medications of antidepressants (including MAOI's) and systemic corticosteroids Patients with a diagnosis of primary insomnia disorders Patients with a diagnosis of severe chronic obstructive pulmonary disease A clinical finding that is untreated (eg, hypertension, poorly controlled diabetes, angina) or that, in the opinion of the investigator, would be negatively affected by the study medication or that would affect the study medication Patients with active substance abuse diagnoses (except tobacco abuse) Known history of intolerance or hypersensitivity to ramelteon or to any other component in the tablet
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Bipolar Disorder Current major depressive episode or mixed episode Bipolar disorder History of suicidal behavior  Requires detoxification from alcohol or other substances Blood pressure greater than 160/90 mm Hg Active medical problems Requires long-term antipsychotic maintenance Becomes manic on mood stabilizers and antidepressants Contraindication to the use of lithium 1 or valproate (including failure to respond) Failure to respond to adequate trials of paroxetine, bupropion, and venlafaxine in the 2 years prior to study entry Failure to respond to adequate trials of olanzapine, haloperidol, and perphenazine in the 2 years prior to study entry Unable or unwilling to consent to treatment Pregnant or lactating
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Bipolar Disorder Persons with Bipolar Condition, Depression, Anxiety, Stress and Insomnia  Persons with severe mental illness that are confined to mental hospitals etc. as defined by the USA Diagnostic and Statistical Manual of Mental Disorders (DSM) are excluded from this clinical trial
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Medullary Thyroid Cancer Histologically confirmed MTC with signs of residual/persistent disease based on tumor marker levels and/or radiographic imaging. Pathologic diagnosis must be confirmed at UWCCC. Grading must be confirmed by pathologic review performed at UWCCC Elevated neuroendocrine markers at least 1 month post -op. In MTC, persistently elevated neuroendocrine markers such as calcitonin and CEA are indicative of persistent disease Disease progression is not required for this trial weeks from the completion of major surgery, chemotherapy, or other systemic therapy or local liver therapy to study registration. Subjects will have had standard of care prior to enrollment. Subjects will have had standard of care prior to enrollment (for example it could total thyroidectomy, central lymph node dissection, and when necessary ipsilateral radical neck dissection but is tailored to the patient) weeks from the completion of radiation therapy to study registration The following laboratory values obtained within 14 days prior to registration Absolute neutrophils count (ANC) ≥ 1000/mm3 Platelets ≥ 75,000/mm3 Hemoglobin ≥ 8.0 g/dL Total bilirubin greater than or equal to 2.0 X the upper limit of normal (ULN)  Gastrointestinal tract disease resulting in an inability to take oral medication (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, bowel obstruction, or inability to swallow the tablets) Significant, active cardiac disease Patients must not be taking the following medications: diuretics, ACE inhibitors, NSAIDs (except aspirin or sulindac), neuroleptics, tetracycline, and COX2 inhibitors Patients with radiographic evidence of disease will be presented the option to undergo a tumor biopsy although this is not mandatory Patients already taking Lithium for any reason are not allowed on study
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bipolar Disorder Patients with diagnosis of Bipolar Disorder (DSM-IV TR) Patients or their legal representatives have provided informed consent  Patients are unable to complete or to understand health questionnaires in Spanish language Patients enrolled in clinical trials or other studies
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 12.0-19.0,  Adolescent - Emotional Problem Smoking 19 years old Major depression Smoke cigarettes Lives with parents No confidentiality issues related to smoking  Non English speaking Suicidal ideation Pregnant
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-39.0,  Bipolar Disorder No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening  Positive test for HIV, Hepatitis B, or Hepatitis C Treatment with known enzyme altering drugs History of allergic or adverse response to lithium, or any comparable or similar product